Forest Laboratories Inc. (FRX)
-NYSE 37.10 
0.07(0.19%) 4:02PM EDT|After Hours
:
37.10 0.00 (0.00%) 4:15PM EDT
| Prev Close: | 37.03 |
|---|
| Open: | 37.21 |
|---|
| Bid: | 36.09 x 200 |
|---|
| Ask: | 38.02 x 200 |
|---|
| 1y Target Est: | 38.85 |
|---|
| Beta: | 0.54 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 37.01 - 37.39 |
|---|
| 52wk Range: | 31.28 - 38.45 |
|---|
| Volume: | 1,057,510 |
|---|
| Avg Vol (3m): | 1,540,790 |
|---|
| Market Cap: | 9.88B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alternative Dosage Forms Create Barriers Against Competition in Generics: A Wall Street Transcript Interview with David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co.Wall Street Transcript(Thu 11:08AM EDT)
- 3 Healthcare Stock Stories For Midweek Wellnessat Wall St. Cheat Sheet(Thu 8:34AM EDT)
- Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPDCNW Group(Thu 4:13AM EDT)
- Almirall, Forest to seek approval for inhaler drug in US, Europeat Reuters(Thu 3:47AM EDT)
- InPlay: Forest Labs and Almirall announce positive results for the Second Phase III study for aclidinium and formoterol combination in COPDBriefing.com(Wed, May 1)
- Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPDBusiness Wire(Wed, May 1)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, Apr 27)
- Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Apr 26)
- Synergy On Sale: Why This Opportunity Shouldn't Be Missedat Seeking Alpha(Thu, Apr 25)
- Loss Widens at IronwoodZacks(Wed, Apr 24)
- Forest Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 23)
- Ironwood Pharma skids following 1st-quarter reportAP(Tue, Apr 23)
- Forest Labs' Earnings DeclineZacks(Tue, Apr 23)
- Forest Labs fiscal 4Q profit plungesAP(Tue, Apr 23)
- Forest Laboratories Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Tue, Apr 23)
Key Statistics
| Forward P/E (1 yr): | 23.78 |
|---|
| P/S (ttm): | 3.18 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 0.89 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.10 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 1.20 |
|---|
Business Summary
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic...
View More